Skip to main content
Premium Trial:

Request an Annual Quote

Waters Mass-Spec Sales Drive 18-Percent Growth in Q4 Revenues

NEW YORK, Jan. 28 (GenomeWeb News) - Driven by a 40 percent growth in sales of its mass-spectrometry technology, Waters yesterday reported Q4 sales of $324 million, up 18 percent over $275 million in sales for the same quarter last year, the company said yesterday.


Doug Berthiaume, Waters chairman, CEO and president, said the increase in revenue reflected greater demand, but also showed a "pretty weak fourth quarter last year," he said. The company did not disclose revenue figures for its mass-spec sales; the 40-percent number was reported in Waters' conference call to investors yesterday.


"The growth is higher than I'd expect the true momentum as being," he said. Mass spec sales were driven by the launch of the Acquity UPLC and Qtof Premier products, the company said.


Waters spent $16.5 million on R&D in the quarter, compared to $16.8 million in the year-ago period.


The company had net income of $72 million for the quarter, up 22 percent over $58 million for the year ago quarter.


Waters reported cash and cash equivalents of $539 million on hand as of Dec. 31.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.